Stent thrombosis rates low in large DES trial 翻译.doc

Stent thrombosis rates low in large DES trial在大样本药物涂层支架研究中支架内血栓发生率低Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT) study reported yesterday.昨日大会对 三年支架内血栓发生率的降低以及在PROTECT研究中得出的 zotarolimus涂层支架和sirolimus涂层支架疗效比较进行了汇报.Presenting the results, William Wijns, from the OLV Ziekenhuis Cardiovascular Center in Aalst, Belgium, said that the decline in rates of stent thrombosis seen recently and in the PROTECT study was probably explained by improvements in patient selection, procedural techniques, and duration of and compliance with dual antiplatelet therapy (DAPT).在给出结论的同时，来自比利时Aalst OLV医院心血管中心的William Wijns讲到：在改善病人双联抗血小板治疗（DAPT）的选择、程序技术、用药时间及依从性方面可以对最近的观察及PROTECT研究中发现的支架内血栓发生率的降低进行解释。The study compared the long-term safety of sirolimus-eluting stents (C-SES) with the zotarolimus-eluting stent (E-ZES) in a broad group of patients and lesions. The primary outcome was definite or probable stent thrombosis at three years, with a secondary outcome of mortality and large non-fatal MI. Investigators randomised 8709 patients into each study arm and, for the primary endpoint, followed them to three years. 这项研究比较了在大量病人及多种病变背景下zotarolimus涂层支架和sirolimus涂层支架的长期安全性。主要终点为明确的或可疑的三年内支架内血栓发生，次要终点为死亡率及非致死性心肌梗死。研究者随机分配8709名病人到各个研究组，并对主要研究终点随访三年。Results showed that, at three years, rates of definite or probable stent thrombosis did not differ between the groups (1.4% for E-ZES and 1.8% for C-SES); other safety and efficacy endpoints were low and sustained up to three years. Rates of death and large non-fatal MI were similar (5.3% vs 6.0%).研究发现在两组之间的三年内明确的或可疑支架血栓形成率无明显差异。（zotarolimus涂层支架组1.4%，sirolimus涂层支架组1.8%）；其它安全性及有效性终点发生率较低并可持续三年时间。死亡率及非致死性心梗发生率基本相似（5.3%对6.0%）。DAPT was used in 96.5% of patients at discharge, 87.8% at one year, 36.6% at two years, and 30.0% at three years.96.5%的出院病人、87.8%出院后一年病人，36.6%出院后两年病人及30.0%出院后三年病人在进行双联抗血小板治疗。The study found a low incidence of definite stent thrombosis in the C-SES arm at one year, when DAPT use was over 85%, but a more than three-fold increase in the rate per year when DAPT use decreased to less than 40%. In the E-ZES arm, the incidence of definite very late stent thrombosis decreased two-fold after one year, despite decreasing DAPT.研究发现出院后一年，在超过85%患者进行双联抗血小板治疗的情况下，sirolimus涂层支架组明确支架内血栓发生率较低。而当患者进行双联抗血小板治疗比例低于40%时，每年的发生率都会提高三倍以上。Commenting on the results, Wijns, said that continued follow-up was necessary to determine whether the rates of stent thromb